MARKET

KURA

KURA

Kura Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.78
-0.07
-0.47%
Closed 16:00 12/13 EST
OPEN
14.79
PREV CLOSE
14.85
HIGH
15.07
LOW
14.54
VOLUME
418.58K
TURNOVER
--
52 WEEK HIGH
21.42
52 WEEK LOW
12.30
MARKET CAP
669.75M
P/E (TTM)
-9.6362
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of KURA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

KURA News

  • Kura Oncology, Inc. (KURA): Hedge Funds Cant Make Up Their Minds
  • Insider Monkey.5d ago
  • Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma at ASH 2019
  • Benzinga.12/08 20:54
  • Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma
  • GlobeNewswire.12/08 17:00
  • The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
  • Benzinga.12/07 13:35

More

Industry

Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Name
Price
%Change

About KURA

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.
More

Webull offers Kura Oncology Inc (KURA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.